Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: SOM230

First Posted Date: 2012-04-17

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT01578928

Locations: 🇿🇦
Novartis Investigative Site, Bloemfontein, Free State, South Africa

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Phase 4

Completed

Conditions: Relapsing-Remitting
Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2012-04-16

Last Posted Date: 2016-06-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT01578330

Locations: 🇹🇷
Novartis Investigative Site, Uskudar / Istanbul, Turkey

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Recurrent Glioblastoma Multiforme
Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Advanced Solid Tumors
Gastroesophageal Junction Cancer
Safety
Dose Escalation
Metastatic Breast Cancer
Gastric Cancer
Triple Negative Metastatic Breast Cancer
Preliminary Efficacy

Interventions: Drug: LDE225
Drug: BKM120

First Posted Date: 2012-04-12

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT01576666

Locations: 🇺🇸
Cedars Sinai Medical Center SC, Los Angeles, California, United States
🇺🇸
Fox Chase Cancer Center FCCC, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Oncology Midtown Texas Oncology, Dallas, Texas, United States

and more 11 locations

A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients

Phase 2

Completed

Conditions: Linitis Plastica
Stomach Diseases
Neoplasms
Adenocarcinoma, Scirrhous
Stomach Neoplasms
Neoplasms by Site

Interventions: Drug: TKI258

First Posted Date: 2012-04-12

Last Posted Date: 2017-02-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 11

Registration Number: NCT01576380

Locations: 🇯🇵
Novartis Investigative Site, Koto, Tokyo, Japan

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Phase 3

Completed

Conditions: Muckle-Wells Syndrome
Familial Cold Autoinflammatory Syndrome
Cryopyrin-associated Periodic Syndromes
Neonatal Onset Multisystem Inflammatory Disease

Interventions: Biological: ACZ885

First Posted Date: 2012-04-12

Last Posted Date: 2018-09-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 17

Registration Number: NCT01576367

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: QVA149
Drug: Tiotropium
Drug: Placebo to tiotropium
Drug: Formoterol
Drug: Placebo to QVA149
Drug: Placebo to formoterol

First Posted Date: 2012-04-10

Last Posted Date: 2014-05-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 934

Registration Number: NCT01574651

Locations: 🇩🇪
Novartis Investigative Site, Zerbst, Germany

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: BKM120
Drug: BKM120 matching placebo

First Posted Date: 2012-04-06

Last Posted Date: 2017-03-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 416

Registration Number: NCT01572727

Locations: 🇺🇸
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas, Texas, United States
🇺🇸
University of Texas Southwestern Medical Center Harry Hines, Dallas, Texas, United States
🇺🇸
Cancer Care Centers of South Texas / HOAST CCC of So. TX- San Antonio, San Antonio, Texas, United States

and more 19 locations

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren

First Posted Date: 2012-04-04

Last Posted Date: 2014-01-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 589

Registration Number: NCT01570686

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Phase 1

Completed

Conditions: Mild and Moderate Renal Impairment

Interventions: Drug: LCZ696

First Posted Date: 2012-04-03

Last Posted Date: 2015-10-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01569815

Locations: 🇷🇸
Novartis Investigative Site, Belgrade, Serbia

Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function

Phase 2

Completed

Conditions: Healthy Volunteer
Renal Impaired
Pharmacokinetics

Interventions: Drug: LCZ696A

First Posted Date: 2012-04-03

Last Posted Date: 2015-09-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 12

Registration Number: NCT01569828

Locations: 🇷🇸
Novartis Investigative Site, Belgrade, Serbia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy